BridgeBio Pharma, Inc. (BBIO)
Nasdaq · Healthcare · Biotechnology
$66.14−1.65%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $12.9B
- Forward P/E
- 2407.7
- 52-week range
- $52.75 – $93.42
- 52-week change
- +24.03%
- EPS (trailing)
- −$3.56
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $502M (+126.26%)
- Operating margin
- −104.2%
- Diluted EPS
- −$3.78
- Free cash flow
- −$447M
From the company’s annual report on SEC EDGAR.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease.
Headquarters: Palo Alto, United States · 999 employees · bridgebio.com